Santen Pharmaceutical Co., Ltd. announced that its board of directors has approved the following management changes. Reasons for change: Shigeo Taniuchi, the company's representative director of the board, President and CEO, offered to resign from his position for personal reasons. The board of directors thereby appointed Representative Director of the Board, Executive Vice President, Takeshi Ito, as President and CEO on September 12, 2022.

Newly appointed Name: Takeshi Ito; New Position: Representative Director of the Board and President; Former Position: Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division. Profile of the newly appointed Representative Director of the Board and President: Date of Birth: July 16, 1959; Profile: April 1982: Joined the Company; December 2002: Head of R&D Integration Department, R&D Division; April 2007: Head of Surgical Division; April 2012: Corporate Officer, Head of Prescription Pharmaceuticals Sales Department, Sales and Marketing Division, Prescription Pharmaceuticals; April 2014: Senior Corporate Officer, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals: April 2016: Executive Corporate Officer, Japan Business, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals; June 2017: Director of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals; April 2019: Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales and Marketing Division; April 2022: Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division. Effective date is September 12, 2022.